ERBB2 and colorectal cancer: This trial demonstrated a median OS of 15.5 months, ORR of 31.9%, and a median PFS of 4.1 months in the HER2-amplified or overexpressed colorectal cancer group, while a particularly higher ORR of 41% was seen amongst patients across all cancer types with IHC staining of 3+ [78].